| ²é¿´: 721 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
ÑÌÔÆÌýÓêÌú¸Ëľ³æ (ÕýʽдÊÖ)
½ð³æ
|
[ÇóÖú]
Çó·ÒëÒ»¶ÎÓ¢ÎÄÎÄÏ×(Óлú»¯Ñ§)
|
|
|
Binding Studies of the Initial Library Against a Panel of CNS Targets. Because other naturally occurring antitussive agents have potent function at one or more CNS receptors (i.e., codeine, along with numerous related agents) (40), we sought to determine if neostenine bound to such targets. Thus, synthetic ()-neostenine and ()-13-epineostenine were screened against 40 individual GPCR and other molecular targets (Fig. 2). The compounds were initially screened at a constant concentration (10 ¦ÌM) to identify possible activity of the compound. Results showing significant activity in the initial screen were selected for ¦Êi determinations using radioligand binding assays. It was determined that ()- neostenine and ()-13-epineostenine only showed binding at the muscarinic M5 receptor and Sig-Rs, respectively, as shown. The somewhat surprising binding differences observed between the epimers suggest a key role for the C-13 substituent. |
» ²ÂÄãϲ»¶
277¡¢Ñ§Ë¶£¬Çóµ÷¼Á ÊýÒ»104£¬
ÒѾÓÐ4È˻ظ´
²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
²ÄÁϹ¤³Ì322·Ö
ÒѾÓÐ13È˻ظ´
277Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
±¾¿ÆÖ£ÖÝ´óѧ£¬Ò»Ö¾Ô¸»ª¶«Ê¦·¶´óѧ282Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó£¬³õÊÔ329£¬Çó»·¾³¿ÆÑ§Ó빤³Ìµ÷¼Á£¡
ÒѾÓÐ10È˻ظ´
071000ÉúÎïѧ£¬Ò»Ö¾Ô¸ÉîÛÚ´óѧ296·Ö£¬Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
²ÄÁÏ¿¼ÑÐÇóµ÷¼Á×Ü·Ö280
ÒѾÓÐ25È˻ظ´
µ÷¼Á
ÒѾÓÐ11È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ3È˻ظ´

8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- É¢½ð: 47
- ºì»¨: 16
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
- ×¢²á: 2011-01-06
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
sltmac(½ð±Ò+1): ллӦÖú£¬»¶Ó³£À´~~ 2011-07-22 16:11:22
ÑÌÔÆÌýÓê(½ð±Ò+15, ·ÒëEPI+1): лл 2011-07-24 19:18:07
sltmac(½ð±Ò+1): ллӦÖú£¬»¶Ó³£À´~~ 2011-07-22 16:11:22
ÑÌÔÆÌýÓê(½ð±Ò+15, ·ÒëEPI+1): лл 2011-07-24 19:18:07
|
Binding Studies of the Initial Library Against a Panel of CNS Targets. ³õ²½ÎÄ¿â¶ÔÒ»×éÖÐÊàÉñ¾ÏµÍ³°Ð±êµÄÇ׺ÍÐÔÑо¿ Because other naturally occurring antitussive agents have potent function at one or more CNS receptors (i.e., codeine, along with numerous related agents) (40), we sought to determine if neostenine bound to such targets.ÓÉÓÚÆäËüÌìÈ»´æÔÚµÄÕò¿È¼ÁÔÚÒ»¸ö»ò¶à¸öÖÐÊàÉñ¾ÏµÍ³ÊÜÌå¾ßÓÐÇ¿µÄ¹¦ÄÜ£¬ÎÒÃÇÊÔͼȷ¶¨ÐÂË¹ÌæÄþÊÇ·ñÓëÕâЩÊÜÌå¾ßÓÐÇ׺ÍÐÔ¡£ Thus, synthetic ( )-neostenine and ( )-13-epineostenine were screened against 40 individual GPCR and other molecular targets (Fig. 2). Òò´Ë¶ÔºÏ³ÉµÄ( )-neostenineºÍ( )-13-epineostenine½øÐÐÁËÕë¶Ô40¸öGPCRºÍÆäËü·Ö×ӰбêµÄɸѡ¡£ The compounds were initially screened at a constant concentration (10 ¦ÌM) to identify possible activity of the compound. ³õ²½É¸Ñ¡²ÉÓù̶¨µÄŨ¶ÈÒÔÈ·¶¨»¯ºÏÎï¿ÉÄܵĻîÐÔ¡£Results showing significant activity in the initial screen were selected for ¦Êi determinations using radioligand binding assays.ÔÚ³õ²½É¸Ñ¡ÖÐÏÔʾÏÔÖø»îÐԵı»Ñ¡³öÀ´ÒÔ·ÅÉäÐÔÅäÌå½áºÏ²â¶¨È·¶¨Ki¡£ It was determined that ( )- neostenine and ( )-13-epineostenine only showed binding at the muscarinic M5 receptor and Sig-Rs, respectively, as shown. ½á¹ûÏÔʾ( )-neostenineºÍ( )-13-epineostenineÖ»·Ö±ð¶Ô¶¾Þ¦¼îM5ÊÜÌåºÍSig-RÏÔʾÇ׺ÍÐÔ¡£ The somewhat surprising binding differences observed between the epimers suggest a key role for the C-13 substituent.²îÏòÒì¹¹ÌåÖ®¼äÕâÖÖ¶àÉÙÁîÈ˾ªÒìµÄÇ׺ÍÐÔ²î±ðÌáʾC-13È¡´ú»ùµÄ¹Ø¼ü×÷Óᣠ|
2Â¥2011-07-22 08:39:59














»Ø¸´´ËÂ¥